The blood transcriptional signature of recombinant human erythropoietin administration and implications for anti-doping strategies
Ontology highlight
ABSTRACT: Scottish trained individuals (SCO; n = 18) living and training at or near sea-level and Kenyan runners (KEN; n = 20) living and training at ~2,150 m received rHuEPO injections of 50 IUâ kg-1 body mass every two days for four weeks. Blood was collected at baseline, during rHuEPO administration and for four weeks after administration. Eight time points per subject were selected for gene expression analysis; two baseline samples, then one sample at two days, two weeks and four weeks after the first rHuEPO injection and one week, two weeks and four weeks after ceasing rHuEPO administration. RNA was extracted from blood stabilized in Tempus Blood RNA tubes (Life Technologies), amplified, labelled and hybridized to Illumina HumanHT-12v4 Expression BeadChips (Illumina). Expression data was analysed using Rank Products with a Benjamini-Hochberg 5% false discovery rate and an additional 1.5 fold-change threshold. The expression profiles of a subset of target genes was further confirmed using QuantiGene Plex assay (Affymetrix) and Limma (linear models for microarray).
INSTRUMENT(S): Illumina BeadArray Reader
ORGANISM(S): Homo sapiens
SUBMITTER: John McClure
PROVIDER: E-MTAB-2874 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA